Immutep TACTI-002 and INSIGHT Global Webcast Slides Transcript
Good morning, everyone. Thank you for joining us for another Immutep investor call to discuss more clinical results from the company's lead product candidate, eftilagimod alpha. Clive Tompkins in Sydney here, your moderator for today. (Event Instructions)
I'd now like to hand you over to -- hand the call over to Marc Voigt, Immutep's CEO, to start the presentation. Marc, are you there?
Thank you, Clive, and welcome, everyone. Early in the morning in Australia, obviously, late in the afternoon in the US, and close to midnight in Europe. So we would like to thank all of you for joining us on the call today, and I hope that everyone is keeping safe and well with your families during the COVID-19 situation obviously still impacting our lives.
On today's webcast, we are excited to take you through the new data from our TACTI-002 and the INSIGHT-004 trial, which was just announced at the virtual ASCO conference. The data relates to our lead
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
